Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome

NCT04371939 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Wiskott-Aldrich Syndrome

Interventions

DRUG: Romiplostim
DRUG: Eltrombopag

Sponsor

Federal Research Institute of Pediatric Hematology, Oncology and Immunology